Marc Carrier/X
Apr 13, 2026, 12:48
Marc Carrier: The Vermont Model Demonstrates the Power of VTE Prevention
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared a post on LinkedIn about a recent article by Chris Holmes et al, published in JCO Oncology Practice:
”Real-world evidence confirms what trials have shown: guideline-based VTE prevention matters.
In high-risk ambulatory cancer patients, a multidisciplinary program (‘Vermont model‘) led to:
- VTE: 3.2% vs 7.7% (OR 0.36)
- 6-month mortality: 16.8% vs 31.3% (OR 0.46)
- Despite strong evidence, uptake remains suboptimal, closing this gap is an immediate opportunity to improve outcomes in cancer care.”
Title: Impact of Venous Thrombosis Prevention in Ambulatory Oncology: Importance of Guideline Adherence
Authors: Chris Holmes, Karlyn Martin, Derek Devine, Jacob Barker, Peter Callas, Karen Libby, Emily Parenteau, Mary Cushman, Steven Ades
Read the Full Article on JCO Oncology Practice
Stay updated on all scientific advances with Hemostasis Today.
-
May 29, 2026, 13:49Tareq Abadl: The Rh Blood Group System – Meet the 5 Antigens That Matter Most
-
May 29, 2026, 13:39Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia
-
May 29, 2026, 12:53Wolfgang Miesbach: The Risk of Deskilling in Modern AI Assisted Medicine
-
May 29, 2026, 12:20Pall T. Onundarson: Is Anonymous Peer Review Always Objective
-
May 29, 2026, 11:59Jolene Ng: New Review Explores the Pathophysiology of Pre-Eclampsia
-
May 29, 2026, 11:44Lynne Baird: Why Expanding Bleed Control Kits Across Public Transport Matters
-
May 29, 2026, 11:30Rumbidzai Mushambi: When ‘Just Hormones’ Delays Real Diagnosis
-
May 29, 2026, 09:53Yassin Taher: Recognizing Clonal Eosinophilic Disorders in Pediatric Hypereosinophilic Syndrome
-
May 29, 2026, 09:52Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk